[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1121098T1 - Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου - Google Patents

Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου

Info

Publication number
CY1121098T1
CY1121098T1 CY181101403T CY181101403T CY1121098T1 CY 1121098 T1 CY1121098 T1 CY 1121098T1 CY 181101403 T CY181101403 T CY 181101403T CY 181101403 T CY181101403 T CY 181101403T CY 1121098 T1 CY1121098 T1 CY 1121098T1
Authority
CY
Cyprus
Prior art keywords
present
relates
against various
tumors
immunotherapy against
Prior art date
Application number
CY181101403T
Other languages
English (en)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CY1121098T1 publication Critical patent/CY1121098T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με πεπτίδια, νουκλεϊκά οξέα και κύτταρα για χρήση σε ανοσοθεραπευτικές μεθόδους. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με την ανοσοθεραπεία του καρκίνου. Η παρούσα εφεύρεση σχετίζεται επιπλέον με όγκο-σχετιζόμενους πεπτιδικούς επιτόπους κυτταροτοξικών Τ-κυττάρων (cytotoxic Τ lymphocytes - CTL), μεμονωμένους ή σε συνδυασμό με άλλα ογκο-σχετιζόμενα πεπτίδια, οι οποίοι λειτουργούν ως ενεργά φαρμακευτικά συστατικά συνθέσεων εμβολίων που διεγείρουν αντικαρκινικές ανοσοαπαντήσεις. Η παρούσα εφεύρεση σχετίζεται με 30 πεπτιδικές αλληλουχίες και τις παραλλαγές τους που προέρχεται από μόρια HLA τάξης I και II ανθρώπινων καρκινικών κυττάρων που μπορούν να χρησιμοποιηθούν σε συνθέσεις εμβολίων για να επιφέρουν αντικαρκινικές ανοσοαπαντήσεις.
CY181101403T 2008-10-01 2018-12-28 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου CY1121098T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP08017921.1A EP2172212B1 (en) 2008-10-01 2008-10-13 Novel immunotherapy against several tumors including neuronal and brain tumors
US10592808P 2008-10-16 2008-10-16
PCT/EP2009/006980 WO2010037514A2 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors
EP09778750.1A EP2341927B1 (en) 2008-10-01 2009-09-28 Composition comprising tumor associated peptides and a vaccine for treatment of glioblastoma and other cancers
EP16165070.0A EP3069728B1 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors

Publications (1)

Publication Number Publication Date
CY1121098T1 true CY1121098T1 (el) 2019-12-11

Family

ID=40342382

Family Applications (11)

Application Number Title Priority Date Filing Date
CY20151100139T CY1116302T1 (el) 2008-10-01 2015-02-12 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY20161100759T CY1119744T1 (el) 2008-10-01 2016-08-02 Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
CY20171100124T CY1118702T1 (el) 2008-10-01 2017-01-26 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY181101403T CY1121098T1 (el) 2008-10-01 2018-12-28 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20191100182T CY1121258T1 (el) 2008-10-01 2019-02-12 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100073T CY1122677T1 (el) 2008-10-01 2020-01-28 Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100449T CY1122913T1 (el) 2008-10-01 2020-05-15 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100594T CY1123089T1 (el) 2008-10-01 2020-06-26 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100606T CY1123098T1 (el) 2008-10-01 2020-06-30 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100613T CY1123113T1 (el) 2008-10-01 2020-07-03 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100984T CY1123526T1 (el) 2008-10-01 2020-10-19 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CY20151100139T CY1116302T1 (el) 2008-10-01 2015-02-12 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY20161100759T CY1119744T1 (el) 2008-10-01 2016-08-02 Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
CY20171100124T CY1118702T1 (el) 2008-10-01 2017-01-26 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου

Family Applications After (7)

Application Number Title Priority Date Filing Date
CY20191100182T CY1121258T1 (el) 2008-10-01 2019-02-12 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100073T CY1122677T1 (el) 2008-10-01 2020-01-28 Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100449T CY1122913T1 (el) 2008-10-01 2020-05-15 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100594T CY1123089T1 (el) 2008-10-01 2020-06-26 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100606T CY1123098T1 (el) 2008-10-01 2020-06-30 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100613T CY1123113T1 (el) 2008-10-01 2020-07-03 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100984T CY1123526T1 (el) 2008-10-01 2020-10-19 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου

Country Status (24)

Country Link
US (19) US8119139B2 (el)
EP (12) EP2172211B1 (el)
JP (10) JP5855940B2 (el)
KR (6) KR101687840B1 (el)
CN (3) CN106986919A (el)
AU (2) AU2009300088B2 (el)
BR (2) BRPI0920759A2 (el)
CA (9) CA2936920C (el)
CY (11) CY1116302T1 (el)
DK (12) DK2172211T3 (el)
EA (3) EA023378B1 (el)
ES (12) ES2536465T3 (el)
HR (12) HRP20160915T1 (el)
HU (11) HUE031030T2 (el)
LT (10) LT2172212T (el)
MX (3) MX2011003539A (el)
NZ (4) NZ624533A (el)
PL (12) PL2172211T3 (el)
PT (12) PT2172211E (el)
RS (12) RS53782B1 (el)
SI (12) SI2172211T1 (el)
TR (2) TR201900809T4 (el)
UA (3) UA110599C2 (el)
WO (2) WO2010037513A1 (el)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023598A2 (en) 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
AU2008281015B2 (en) * 2007-07-27 2012-07-26 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
EP2119726B2 (en) 2008-05-14 2017-11-29 Immatics Biotechnologies GmbH Novel and powerful MHC-class II peptides derived from survivin and neurocan
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2011293522B2 (en) * 2010-08-24 2015-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
SG191154A1 (en) * 2010-12-14 2013-07-31 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2013052158A2 (en) * 2011-04-26 2013-04-11 William Marsh Rice University Targeted nanovectors and their use for treatment of brain tumors
ES2856091T3 (es) 2011-09-14 2021-09-27 Univ Northwestern Nanoconjugados capaces de atravesar la barrera hematoencefálica
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2804602B1 (en) 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
US10485858B2 (en) * 2012-05-16 2019-11-26 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
ES3009064T3 (en) * 2013-08-05 2025-03-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer including nsclc
TWI776192B (zh) * 2013-08-05 2022-09-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（四）
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
KR102021982B1 (ko) 2014-04-25 2019-09-18 블루버드 바이오, 인코포레이티드. Mnd 프로모터 키메라 항원 수용체
KR102161927B1 (ko) 2014-04-25 2020-10-06 블루버드 바이오, 인코포레이티드. 양자 세포 치료제를 제조하는 개선된 방법
WO2015182668A1 (ja) * 2014-05-28 2015-12-03 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
NZ726989A (en) * 2014-06-06 2020-08-28 Bluebird Bio Inc Improved t cell compositions
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
JP6706244B2 (ja) 2014-07-24 2020-06-03 ブルーバード バイオ， インコーポレイテッド Ｂｃｍａキメラ抗原受容体
CA2963184C (en) * 2014-11-06 2020-11-24 Ose Immunotherapeutics Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
SMT202100594T1 (it) 2014-12-12 2021-11-12 2Seventy Bio Inc Recettori chimerici dell'antigene bcma
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR102435015B1 (ko) 2014-12-23 2022-08-22 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
MY199500A (en) 2015-03-17 2023-11-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
KR20240161207A (ko) * 2015-05-06 2024-11-12 이매틱스 바이오테크놀로지스 게엠베하 결장직장 암종(crc) 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드와 이의 골격의 조합
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3650043A3 (en) 2015-06-09 2020-07-29 The Board of Regents of the University of Oklahoma Compositions and treatments for haemophilus influenzae
JP6892443B2 (ja) 2015-06-24 2021-06-23 イモデュロン セラピューティクス リミテッド がん治療で使用するためのチェックポイント阻害剤及び全細胞マイコバクテリウム
MY191654A (en) 2015-07-01 2022-07-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
UA124411C2 (uk) * 2015-07-06 2021-09-15 Імматікс Біотекнолоджіс Гмбх Фармацевтично прийнятна сіль пептиду та її застосування для лікування раку
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
CA3223546A1 (en) 2015-08-28 2017-03-09 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
JP7572700B2 (ja) 2015-10-19 2024-10-24 ユニバーシティ オブ メリーランド ボルチモア 改変ヒト初代血液樹状細胞株を生成するための方法
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
PL3430037T3 (pl) 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
SG11201808627RA (en) * 2016-04-06 2018-10-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
DK3518948T5 (da) * 2016-10-03 2024-09-02 Ottawa Hospital Res Inst Sammensætninger og fremgangsmåder til forstærkning af vækst, spredning og onkolytisk og immunterapeutisk virkningsgrad af onkolytiske rna-vira
CN110022906A (zh) 2016-11-04 2019-07-16 蓝鸟生物公司 抗bcma car t细胞组合物
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
ES2973548T3 (es) * 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
CN112210010B (zh) 2017-01-06 2023-12-05 优特力克斯有限公司 抗-人4-1bb抗体及其应用
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) * 2017-02-28 2018-09-07 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
CA3062591A1 (en) * 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
IL274799B2 (en) 2017-11-22 2025-05-01 Gritstone Bio Inc Reducing junction epitope presentation for neoantigens
US11766455B2 (en) * 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
MX2020010701A (es) * 2018-04-11 2021-01-20 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer.
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
CN113645997B (zh) 2019-03-29 2024-12-17 英特维特国际股份有限公司 在液体组合物中对活的柔膜菌纲细菌的稳定化
CN113939320A (zh) 2019-04-05 2022-01-14 医尔利有限公司 用于合成的生物标志物的改进的方法和组合物
CN114207675A (zh) 2019-05-28 2022-03-18 佩治人工智能公司 用于数字病理学的用于处理图像以针对所处理的图像制备载片的系统和方法
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
WO2021142300A2 (en) * 2020-01-10 2021-07-15 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
AU2020431140A1 (en) * 2020-02-24 2022-08-18 The Regents Of The University Of California Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113444149A (zh) * 2020-03-18 2021-09-28 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
WO2021202810A2 (en) * 2020-03-31 2021-10-07 Walking Fish Therapeutics Modified b cells and methods of use thereof
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
US20220062406A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
NZ192465A (en) 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
WO1998003197A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1998031797A1 (en) 1997-01-15 1998-07-23 Zymogenetics, Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
CA2243984A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham P.L.C. Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2002529048A (ja) * 1997-12-02 2002-09-10 メダレツクス・インコーポレーテツド 抗−Ｆｃ受容体結合成分を発現する細胞
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2328992A1 (en) * 1998-04-27 1999-11-04 Northwest Hospital Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6960651B2 (en) * 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
WO2001055322A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020090672A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU2001279581A1 (en) * 2000-09-06 2002-03-22 Friederike Muller Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1356048A2 (en) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046767A2 (en) * 2000-12-08 2002-06-13 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
WO2004015390A2 (en) * 2002-08-09 2004-02-19 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
JP2006516258A (ja) * 2002-12-27 2006-06-29 シェンジェンシチンファユアンシンシェンウイヤオカジヨウシャンゴンシ ワクチンおよび抗腫瘍ワクチンを調製する方法
EP1615552A4 (en) 2003-04-04 2006-11-29 Pharmacyclics Inc SAPPHYRINE AND ITS USES
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
EP1712620A4 (en) * 2004-01-23 2008-05-28 Greenpeptide Co Ltd EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
EP1642905B1 (en) * 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
EP1835027B1 (en) * 2004-12-07 2015-02-25 Toray Industries, Inc. Novel cancer antigen peptide and the use thereof
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
PL1806359T3 (pl) 2005-09-05 2010-08-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II
EP1938104A2 (en) 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
EP2089423B1 (en) * 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2008039874A2 (en) * 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2679743A1 (en) * 2007-03-06 2008-09-12 Barry G. Arnason Methods and compositions involving polymeric immunoglobulin fusion proteins
EP2280731A1 (en) * 2008-04-09 2011-02-09 Technion Research and Development Foundation, Ltd. Anti human immunodeficiency antibodies and uses thereof
EP2113253B1 (en) * 2008-04-30 2010-03-31 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
EP2172211B1 (en) 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
HUE049074T2 (hu) * 2014-05-28 2020-08-28 Nono Inc TAT-NR2B9c klorid-sója
EA201892333A1 (ru) 2016-04-21 2019-03-29 Имматикс Байотекнолоджиз Гмбх Иммунотерапия меланомы и других видов рака
EP3679065A4 (en) * 2017-09-06 2021-05-19 California Institute of Technology BIFUNCTIONAL SIGNALING AND RECEPTORS PRESENTING ANTIGENS (SABR)

Also Published As

Publication number Publication date
PL3124043T3 (pl) 2020-07-27
LT3069728T (lt) 2019-02-11
HRP20201025T8 (hr) 2022-01-07
JP2017018102A (ja) 2017-01-26
PT3120869T (pt) 2020-09-22
SI3111952T1 (sl) 2019-01-31
US9993540B2 (en) 2018-06-12
US10047123B2 (en) 2018-08-14
DK2331118T3 (da) 2017-01-09
HUE051030T2 (hu) 2021-01-28
CA2936868C (en) 2019-10-22
EA032437B1 (ru) 2019-05-31
HUE050428T2 (hu) 2020-12-28
DK3069728T3 (en) 2019-02-25
EP2172212A3 (en) 2010-04-14
SI3132801T1 (sl) 2020-03-31
US20160376313A1 (en) 2016-12-29
US20150125478A1 (en) 2015-05-07
US8895514B2 (en) 2014-11-25
EP3120868A1 (en) 2017-01-25
JP6150859B2 (ja) 2017-06-21
US20170326217A1 (en) 2017-11-16
HRP20182151T1 (hr) 2019-02-08
SI2172212T1 (sl) 2016-12-30
ES2536465T3 (es) 2015-05-25
US20130309193A1 (en) 2013-11-21
BRPI0920791A2 (pt) 2019-12-10
NZ591882A (en) 2012-12-21
HUE049367T2 (hu) 2020-09-28
CY1122913T1 (el) 2021-10-29
HUE049366T2 (hu) 2020-09-28
CA2936887C (en) 2019-11-12
HUE031030T2 (en) 2017-06-28
EP3120868B1 (en) 2020-04-08
CN102170901B (zh) 2015-01-07
ES2770090T3 (es) 2020-06-30
CN102170900B (zh) 2016-10-26
DK3111952T3 (en) 2019-01-28
SI3106175T1 (sl) 2020-08-31
US10046037B2 (en) 2018-08-14
ES2788129T8 (es) 2020-11-04
DK3124043T3 (da) 2020-05-04
RS58443B1 (sr) 2019-04-30
US20190010190A1 (en) 2019-01-10
PT3120868T (pt) 2020-07-16
US8653035B2 (en) 2014-02-18
HRP20160915T1 (hr) 2016-10-07
DK3120870T3 (da) 2020-06-22
US10941181B2 (en) 2021-03-09
KR20220058655A (ko) 2022-05-09
CY1119744T1 (el) 2018-06-27
LT2172212T (lt) 2016-11-10
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
JP5855940B2 (ja) 2016-02-09
CY1123089T1 (el) 2021-10-29
HUE047365T2 (hu) 2020-04-28
DK3120869T3 (da) 2020-08-10
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
US20210253637A1 (en) 2021-08-19
DK2172212T3 (da) 2016-12-19
PL3120868T3 (pl) 2020-08-24
PL2172211T3 (pl) 2015-05-29
ES2708654T3 (es) 2019-04-10
PT3120870T (pt) 2020-07-01
KR20180088494A (ko) 2018-08-03
EP3106175B1 (en) 2020-04-01
RS60381B1 (sr) 2020-07-31
EP2172212B1 (en) 2016-10-05
JP2012504393A (ja) 2012-02-23
SI3120869T1 (sl) 2020-10-30
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
EP2331118A1 (en) 2011-06-15
US11208434B2 (en) 2021-12-28
EP3124043B1 (en) 2020-04-29
KR20110074894A (ko) 2011-07-04
KR102133402B1 (ko) 2020-07-14
EP3069728B1 (en) 2018-11-14
US20160376317A1 (en) 2016-12-29
HUE041446T2 (hu) 2019-05-28
UA110599C2 (uk) 2016-01-25
HRP20161504T1 (hr) 2016-12-30
US10919931B2 (en) 2021-02-16
CA2936870C (en) 2019-11-26
EA201100587A1 (ru) 2011-10-31
PT3069728T (pt) 2019-02-13
WO2010037514A3 (en) 2010-06-03
KR20160103558A (ko) 2016-09-01
CA2739387A1 (en) 2010-04-08
HRP20200988T1 (hr) 2020-10-16
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
JP5753783B2 (ja) 2015-07-22
BRPI0920791B8 (pt) 2022-02-15
MX2011003539A (es) 2011-06-20
LT2331118T (lt) 2016-12-27
HRP20200110T1 (hr) 2020-05-15
CN102170901A (zh) 2011-08-31
CA2936920A1 (en) 2010-04-08
CA2936868A1 (en) 2010-04-08
US8961985B2 (en) 2015-02-24
UA103202C2 (ru) 2013-09-25
JP6294914B2 (ja) 2018-03-14
RS60338B1 (sr) 2020-07-31
JP2016047825A (ja) 2016-04-07
ES2710608T3 (es) 2019-04-26
RS60385B1 (sr) 2020-07-31
PL2331118T3 (pl) 2017-05-31
HK1161106A1 (en) 2012-08-24
PT3111952T (pt) 2019-02-05
TR201900809T4 (tr) 2019-02-21
US10227381B2 (en) 2019-03-12
CN106986919A (zh) 2017-07-28
CY1118702T1 (el) 2017-07-12
RS53782B1 (en) 2015-06-30
WO2010037513A1 (en) 2010-04-08
HRP20200722T1 (hr) 2020-10-16
US20160355550A1 (en) 2016-12-08
RS55043B1 (sr) 2016-12-30
JP2017018101A (ja) 2017-01-26
CA2936982C (en) 2019-12-03
SI3120868T1 (sl) 2020-08-31
JP6367266B2 (ja) 2018-08-01
DK2172211T3 (en) 2015-02-16
CN102170900A (zh) 2011-08-31
JP2012504563A (ja) 2012-02-23
HRP20201015T1 (hr) 2020-10-16
EP3106175A1 (en) 2016-12-21
US20160376315A1 (en) 2016-12-29
EP2341927A2 (en) 2011-07-13
KR101883426B1 (ko) 2018-07-31
US20100158931A1 (en) 2010-06-24
PT3124043T (pt) 2020-05-12
NZ591855A (en) 2012-11-30
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
CY1122677T1 (el) 2021-03-12
PT3132801T (pt) 2020-02-04
DK3132801T3 (da) 2020-02-10
EP2172212A2 (en) 2010-04-07
PL3120870T3 (pl) 2020-07-27
US20130004456A1 (en) 2013-01-03
US12221493B2 (en) 2025-02-11
ES2584245T3 (es) 2016-09-26
HUE029360T2 (en) 2017-02-28
JP2016145210A (ja) 2016-08-12
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
ES2804723T3 (es) 2021-02-09
US12234298B2 (en) 2025-02-25
EP3120870A1 (en) 2017-01-25
PL3111952T3 (pl) 2019-04-30
CA2936869C (en) 2019-08-06
EP3132801B1 (en) 2019-10-30
CA2936870A1 (en) 2010-04-08
DK3120868T3 (da) 2020-06-22
JP2017029135A (ja) 2017-02-09
BRPI0920759A2 (pt) 2016-03-08
HRP20170115T1 (hr) 2017-03-24
EP3111952B1 (en) 2018-10-31
CA2936982A1 (en) 2010-04-08
CA2739384C (en) 2017-05-02
NZ603016A (en) 2014-05-30
PL3132801T3 (pl) 2020-06-15
PT2172211E (pt) 2015-03-09
RS55543B1 (sr) 2017-05-31
TR201900852T4 (tr) 2019-02-21
US20210261614A1 (en) 2021-08-26
KR20200085381A (ko) 2020-07-14
US20160376314A1 (en) 2016-12-29
LT3132801T (lt) 2020-02-10
AU2009300088B2 (en) 2014-09-04
EP3120869B1 (en) 2020-07-22
KR101756488B1 (ko) 2017-07-11
HRP20201015T8 (hr) 2022-01-21
LT3111952T (lt) 2018-12-27
CA2936869A1 (en) 2010-04-08
EP2341927B1 (en) 2016-05-04
LT3120869T (lt) 2020-11-10
HK1159526A1 (zh) 2012-08-03
CY1116302T1 (el) 2017-02-08
SI2331118T1 (sl) 2017-01-31
SI3120870T1 (sl) 2020-08-31
JP2017023136A (ja) 2017-02-02
MX2011003540A (es) 2011-06-20
AU2009300087B2 (en) 2014-09-04
PT2331118T (pt) 2017-02-06
EP3120869A1 (en) 2017-01-25
US20120141517A1 (en) 2012-06-07
CY1123526T1 (el) 2022-03-24
AU2009300088A1 (en) 2010-04-08
PT2172212T (pt) 2016-12-22
LT3106175T (lt) 2020-08-10
EP2172211A1 (en) 2010-04-07
ES2607460T3 (es) 2017-03-31
LT3120868T (lt) 2020-08-10
HUE042115T2 (hu) 2019-06-28
HUE049364T2 (hu) 2020-09-28
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
KR102392070B1 (ko) 2022-04-29
SI3124043T1 (sl) 2020-07-31
ES2788129T3 (es) 2020-10-20
CA2936924C (en) 2019-07-16
HUE030296T2 (en) 2017-04-28
EP3111952A1 (en) 2017-01-04
US11136352B2 (en) 2021-10-05
HRP20201228T1 (hr) 2021-02-05
JP6297632B2 (ja) 2018-03-20
AU2009300087A1 (en) 2010-04-08
HRP20201025T1 (hr) 2020-12-25
HRP20150223T8 (hr) 2015-07-03
CA2936920C (en) 2019-12-03
JP2017000148A (ja) 2017-01-05
EP3069728A1 (en) 2016-09-21
EP3120870B1 (en) 2020-04-01
EA023378B1 (ru) 2016-05-31
RS58229B1 (sr) 2019-03-29
CA2739387C (en) 2019-10-29
CY1121258T1 (el) 2020-05-29
PL3106175T3 (pl) 2020-08-24
ES2802227T3 (es) 2021-01-18
JP2014239681A (ja) 2014-12-25
RS60386B1 (sr) 2020-07-31
EA201100586A1 (ru) 2011-10-31
US8119139B2 (en) 2012-02-21
RS55531B1 (sr) 2017-05-31
EP3124043A1 (en) 2017-02-01
US20210238227A1 (en) 2021-08-05
PT2341927T (pt) 2016-08-02
KR101687840B1 (ko) 2016-12-19
US10047124B2 (en) 2018-08-14
CA2936887A1 (en) 2010-04-08
EP2172211B1 (en) 2014-12-03
DK2341927T3 (en) 2016-08-15
EA023013B1 (ru) 2016-04-29
EP3132801A1 (en) 2017-02-22
WO2010037514A2 (en) 2010-04-08
US8318677B2 (en) 2012-11-27
HRP20150223T1 (hr) 2015-06-05
PT3106175T (pt) 2020-07-01
PL2341927T3 (pl) 2016-11-30
NZ624533A (en) 2015-09-25
CA2936924A1 (en) 2010-04-08
JP6214066B2 (ja) 2017-10-18
CY1123113T1 (el) 2021-10-29
ES2819244T3 (es) 2021-04-15
SI3069728T1 (sl) 2019-03-29
EP2331118B1 (en) 2016-10-26
JP6294913B2 (ja) 2018-03-14
JP5883476B2 (ja) 2016-03-15
KR20110082155A (ko) 2011-07-18
HRP20190202T1 (hr) 2019-03-22
US20210347822A1 (en) 2021-11-11
CY1123098T1 (el) 2021-10-29
DK3106175T3 (da) 2020-06-22
US10906936B2 (en) 2021-02-02
EA201401104A1 (ru) 2015-05-29
CA2739384A1 (en) 2010-04-08
MX338294B (es) 2016-04-11
ES2612466T3 (es) 2017-05-17
PL2172212T3 (pl) 2017-04-28
BRPI0920791B1 (pt) 2022-01-18
US20160376316A1 (en) 2016-12-29

Similar Documents

Publication Publication Date Title
CY1121258T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY1122235T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρικου καρκινου
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CY1117115T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
CY1117171T1 (el) Καινοτομα και ισχυρα πεπτιδια mch tαξης ιι προερχομενα απο την σουρβιβινη
EA201690016A1 (ru) Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл
CY1124847T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων
CY1122083T1 (el) Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ)
CY1119253T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
CY1116819T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και γαστρικου καρκινου
EA201990696A1 (ru) Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга